Evidence map›Paper›PMID 34761824›Full record

ArticleJournal of medical virology2022

First wave of COVID-19 in Venezuela: Epidemiological, clinical, and paraclinical characteristics of first cases.

David A Forero-Peña, Fhabián S Carrión-Nessi, Daniela L Mendoza-Millán, Óscar D Omaña-Ávila, Mario D Mejía-Bernard, Natasha A Camejo-Ávila, David M Flora-Noda, Viledy L Velásquez, Fabián R Chacón-Labrador, Juan M Doval-Fernández and 13 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

David A Forero-PeñaDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0002-8065-8464
Fhabián S Carrión-NessiDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0003-4415-8646
Daniela L Mendoza-MillánDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0003-1481-5166
Óscar D Omaña-ÁvilaDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0002-4505-215X
Mario D Mejía-BernardDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0002-5480-7200
Natasha A Camejo-ÁvilaDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0001-9131-7852
David M Flora-NodaDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0001-8153-4458
Viledy L VelásquezDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0003-0261-3559
Fabián R Chacón-LabradorDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0001-7960-6184
Juan M Doval-FernándezDepartment of Infectious Diseases, Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolivar, Venezuela.ORCID 0000-0002-2580-668X
Andrea L MaricutoDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0002-3557-0877
María E GrilletVector Biology Laboratory, Institute of Zoology and Tropical Ecology, Central University of Venezuela, Caracas, Venezuela.ORCID 0000-0003-2922-6751
Juan V Hernández-VillenaVector Biology Laboratory, Institute of Zoology and Tropical Ecology, Central University of Venezuela, Caracas, Venezuela.ORCID 0000-0001-9006-8380
María F Vincenti-GonzálezDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-1364-1774
Alberto E Paniz-MondolfiDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States.ORCID 0000-0003-1259-1736
José OrejasDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-7279-9024
Verónica I RodríguezDepartment of Medicine, "Luis Razetti" School of Medicine, Central University of Venezuela, Caracas, Venezuela.ORCID 0000-0003-3887-7097
Mariana B ContrerasDepartment of Medicine, "Luis Razetti" School of Medicine, Central University of Venezuela, Caracas, Venezuela.ORCID 0000-0003-2338-7722
Rafael N GuevaraDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0003-4266-4350
Martín CarballoDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0003-3668-6828
Jocays CalderaDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0003-0709-4006
María C RedondoDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0001-6339-8798
María E LandaetaDepartment of Infectious Diseases, University Hospital of Caracas, Caracas, Venezuela.ORCID 0000-0001-9295-7296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has particularly affected countries with weakened health services in Latin America, where proper patient management could be a critical step to address the epidemic. In this study, we aimed to characterize and identify which epidemiological, clinical, and paraclinical risk factors defined COVID-19 infection from the first confirmed cases through the first epidemic wave in Venezuela. A retrospective analysis of consecutive suspected cases of COVID-19 admitted to a sentinel hospital was carried out, including 576 patient cases subsequently confirmed for severe acute respiratory syndrome coronavirus 2 infection. Of these, 162 (28.1%) patients met the definition criteria for severe/critical disease, and 414 (71.2%) were classified as mild/moderate disease. The mean age was 47 (SD 16) years, the majority of which were men (59.5%), and the most frequent comorbidity was arterial hypertension (23.3%). The most common symptoms included fever (88.7%), headache (65.6%), and dry cough (63.9%). Severe/critical disease affected mostly older males with low schooling (p < 0.001). Similarly, higher levels of glycemia, urea, aminotransferases, total bilirubin, lactate dehydrogenase, and erythrocyte sedimentation rate were observed in severe/critical disease patients compared to those with mild/moderate disease. Overall mortality was 7.6% (44/576), with 41.7% (28/68) dying in hospital. We identified risk factors related to COVID-19 infection, which could help healthcare providers take appropriate measures and prevent severe clinical outcomes. Our results suggest that the mortality registered by this disease in Venezuela during the first epidemic wave was underestimated. An increase in fatalities is expected to occur in the coming months unless measures that are more effective are implemented to mitigate the epidemic while the vaccination process is ongoing.

Indexed as

COVID-19FemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesSARS-CoV-2Venezuelaclinical characteristicsCOVID-19epidemiologySARS-CoV-2Venezuela

Identifiers

PMID34761824
PMCPMC8662004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.